Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 559

Results For "RI"

11124 News Found

Concord Biotech announces successful completion EU GMP inspection at its API facility
News | July 18, 2025

Concord Biotech announces successful completion EU GMP inspection at its API facility

This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance


Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2
Drug Approval | July 18, 2025

Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2

The company is addressing these observations comprehensively


Shilpa Medicare receives EIR from USFDA for Unit VI, Bengaluru
Drug Approval | July 17, 2025

Shilpa Medicare receives EIR from USFDA for Unit VI, Bengaluru

This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms


SMS Lifesciences India receives EIR with VAI status from USFDA for API facility at Kazipally
Drug Approval | July 17, 2025

SMS Lifesciences India receives EIR with VAI status from USFDA for API facility at Kazipally

The receipt of EIR reaffirms the company's commitment to maintaining global quality standards


Lupin launches Loteprednol Etabonate ophthalmic suspension 0.5% in US
News | July 17, 2025

Lupin launches Loteprednol Etabonate ophthalmic suspension 0.5% in US

Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva


Corona Remedies acquires 7 brands from Bayer's pharma division in India
News | July 17, 2025

Corona Remedies acquires 7 brands from Bayer's pharma division in India

This marks the fourth acquisition by Corona Remedies from multinational corporations


Waters, BD biosciences unit agree to $17.5 billion merger
News | July 16, 2025

Waters, BD biosciences unit agree to $17.5 billion merger

The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026


FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%
Drug Approval | July 15, 2025

FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%

Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,